Gallant, a Los Angeles, CA-based animal biotech company, raised $11m in funding.
Backers included Maveron, Bold Capital Partners, Bling Capital, Science Inc. and more.
The company is using the funds for research and development, clinical studies to advance treatments and education campaigns on stem cell therapy.
Founded by DogVacay founder & CEO Aaron Hirschhorn and also led by Chief Scientific Officer Dr. Linda Black, Gallant has developed a non-invasive way to collect stem cells, which have been used to treat ailments ranging from torn ligaments to arthritis to kidney disease.
The company is also announcing the acquisition of the veterinary division of Cook-Regentec, including their intellectual property, existing stem cell banking operations and their pipeline of cell therapy products derived from reproductive tissue.
Richard Jennings, the CEO of cord blood banking company California Cryobank, and Darryl Rawlings, the founder and chief executive officer of Trupanion, sit on Gallant’s board. Its advisors include Art Antin, the co-founder of VCA, and Dr. David Haworth, the former president of PetSmart Charities in the US and Canada.